Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Tuberous sclerosis complex (TSC) is a genetic disease in which overactivation of mechanistic target of rapamycin (mTOR) signaling leads to the growth of benign hamartomas in multiple organs, including the brain, and is associated with a high rate of epilepsy and neurological deficits. The mTOR inhibitor everolimus has been used in the treatment of subependymal giant cell astrocytomas and renal angiomyolipomas in patients with TSC. This article describes the case of a 13-year-old girl with TSC-associated epilepsy with refractory generalized seizures who initiated treatment with everolimus and experienced subsequent improvement in several TSC manifestations, including a reduction in seizure frequency from clusters of two or three daily to one every 2 to 4. weeks after 1.5. years of treatment.

Original languageEnglish (US)
Pages (from-to)63-66
Number of pages4
JournalEpilepsy and Behavior Case Reports
Volume4
DOIs
StatePublished - Jan 1 2015

Fingerprint

Tuberous Sclerosis
Sirolimus
Epilepsy
Seizures
Angiomyolipoma
Inborn Genetic Diseases
Hamartoma
Astrocytoma
Therapeutics
Kidney
Everolimus
Brain
Growth

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Cite this

@article{2b5f5b422c7a48d19f4b2ac9a5bcaa7b,
title = "Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy",
abstract = "Tuberous sclerosis complex (TSC) is a genetic disease in which overactivation of mechanistic target of rapamycin (mTOR) signaling leads to the growth of benign hamartomas in multiple organs, including the brain, and is associated with a high rate of epilepsy and neurological deficits. The mTOR inhibitor everolimus has been used in the treatment of subependymal giant cell astrocytomas and renal angiomyolipomas in patients with TSC. This article describes the case of a 13-year-old girl with TSC-associated epilepsy with refractory generalized seizures who initiated treatment with everolimus and experienced subsequent improvement in several TSC manifestations, including a reduction in seizure frequency from clusters of two or three daily to one every 2 to 4. weeks after 1.5. years of treatment.",
author = "James Wheless",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.ebcr.2015.06.008",
language = "English (US)",
volume = "4",
pages = "63--66",
journal = "Epilepsy and Behavior Case Reports",
issn = "2213-3232",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy

AU - Wheless, James

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Tuberous sclerosis complex (TSC) is a genetic disease in which overactivation of mechanistic target of rapamycin (mTOR) signaling leads to the growth of benign hamartomas in multiple organs, including the brain, and is associated with a high rate of epilepsy and neurological deficits. The mTOR inhibitor everolimus has been used in the treatment of subependymal giant cell astrocytomas and renal angiomyolipomas in patients with TSC. This article describes the case of a 13-year-old girl with TSC-associated epilepsy with refractory generalized seizures who initiated treatment with everolimus and experienced subsequent improvement in several TSC manifestations, including a reduction in seizure frequency from clusters of two or three daily to one every 2 to 4. weeks after 1.5. years of treatment.

AB - Tuberous sclerosis complex (TSC) is a genetic disease in which overactivation of mechanistic target of rapamycin (mTOR) signaling leads to the growth of benign hamartomas in multiple organs, including the brain, and is associated with a high rate of epilepsy and neurological deficits. The mTOR inhibitor everolimus has been used in the treatment of subependymal giant cell astrocytomas and renal angiomyolipomas in patients with TSC. This article describes the case of a 13-year-old girl with TSC-associated epilepsy with refractory generalized seizures who initiated treatment with everolimus and experienced subsequent improvement in several TSC manifestations, including a reduction in seizure frequency from clusters of two or three daily to one every 2 to 4. weeks after 1.5. years of treatment.

UR - http://www.scopus.com/inward/record.url?scp=84939154517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939154517&partnerID=8YFLogxK

U2 - 10.1016/j.ebcr.2015.06.008

DO - 10.1016/j.ebcr.2015.06.008

M3 - Article

AN - SCOPUS:84939154517

VL - 4

SP - 63

EP - 66

JO - Epilepsy and Behavior Case Reports

JF - Epilepsy and Behavior Case Reports

SN - 2213-3232

ER -